Aquagenic urticaria with extracutaneous manifestations

Allergy and Asthma Proceedings

Volumn 26, Issue 3, 2005, Pages 217-220

  Baptist, Alan P ^a,b   Baldwin, James L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b 3918 Taubman Center No 0380 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; SERTRALINE; WATER;

ADULT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; HEADACHE; HUMAN; URTICARIA;

ADULT; FEMALE; HEADACHE; HUMANS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; URTICARIA; WATER;

EID: 24944468606     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Shelley WB, and Rawnsley HM. Aquagenic urticaria. Contact sensitivity reaction to water. JAMA 189:895-898, 1964.
2. Hide M, Yamamura Y, Sanada S, and Yamamoto S. Aquagenic urticaria: A case report. Acta Derm Venereol 80:148-149, 2000.
3. Schwarze G, and Liebeskind H. Urticaria with follicular-type weals following cold water contact. Hautarzt 25:86-87, 1974.
4. Panconesi E, and Lotti T. Aquagenic urticaria. Clin Dermatol 5:49-51, 1987.
5. Gallo R, Cacciapuoti M, Cozzani E, and Guarrera M. Localized aquagenic urticaria dependent on saline concentration. Contact Dermatitis 44:110-111, 2001.
6. Blanco J, Ramirez M, Garcia F, et al. Localized aquagenic urticaria. Contact Dermatitis 42:303-304, 2000.
7. Luong KV, and Nguyen LT. Aquagenic urticaria: Report of a case and review of the literature. Ann Allergy Asthma Immunol 80:483-485, 1998.
8. Treudler R, Tebbe B, Steinhoff M, and Orfanos CE. Familial aquagenic urticaria associated with familial lactose intolerance. J Am Acad Dermatol 47:611-613, 2002.
9. Fearfield LA, Gazzard B, and Bunker CB. Aquagenic urticaria and human immunodeficiency virus infection: Treatment with stanozolol. Br J Dermatol 137:620-622, 1997.
10. Bonnetblanc JM, Andrieu-Pfahl F, Meraud JP, and Roux J. Familial aquagenic urticaria. Dermatologica 158:468-470, 1979.
11. Juhlin L, and Malmros-Enander I. Familial polymorphous light eruption with aquagenic urticaria: Successful treatment with PUVA. Photodermatol 3:346-349, 1986.
12. Czarnetzki BM, Breetholt KH, and Traupe H. Evidence that water acts as a carrier for an epidermal antigen in aquagenic urticaria. J Am Acad Dermatol 15:623-627, 1986.
13. Sibbald RG, Black AK, Eady RA, et al. Aquagenic urticaria: Evidence of cholinergic and histaminergic basis. Br J Dermatol 105:297-302, 1981.
14. Chalamidas SL, and Charles CR. Aquagenic urticaria. Arch Dermatol 104:541-546, 1971.
15. Gimenez-Arnau A, Serra-Baldrich E, and Camarasa JG. Chronic aquagenic urticaria. Acta Derm Venereol 72:389, 1992.
16. Martinez-Escribano JA, Quecedo E, De la Cuadra J, Frias J, et al. Treatment of aquagenic urticaria with PUVA and astemizole. J Am Acad Dermatol 36:118-119, 1997.
17. Parker RK, Crowe MJ, and Guin JD. Aquagenic urticaria. Cutis 50:283-284, 1992.
18. Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders cnafp. Cephalalgia 8(suppl 7):19, 1988.
19. Welch KM. Drug therapy of migraine. N Engl J Med 329:1476-1483, 1993.
20. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1:658-660, 1995.
21. Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 53:180-184, 1996.
22. Chugani DC, Niimura K, Chaturvedi S, et al. Increased brain serotonin synthesis in migraine. Neurology 53:1473-1479, 1999.
23. Haimart M, Pradalier A, Launay JM, et al. Whole blood and plasma histamine in common migraine. Cephalalgia 7:39-42, 1987.
24. Ramadan NM, Schultz LL, and Gilkey SJ. Migraine prophylactic drugs: Proof of efficacy, utilization, and cost. Cephalalgia 17:73-80, 1997.
25. Adly C, Straumanis J, and Chesson A. Fluoxetine prophylaxis of migraine. Headache 32:101-104, 1992.
26. Stone KJ, Viera AJ, and Parman CL. Off-label applications for SSRIs. Am Fam Physician 68:498-504, 2003.
27. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 32(suppl 1):1-21, 1997.
28. Vaswani M, Linda FK, and Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: A comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27:85-102, 2003.
29. Schuessler B, and Baessler K. Pharmacologic treatment of stress urinary incontinence: Expectations for outcome. Urology 62(suppl 1):31-38, 2003.
30. Gupta MA, and Gupta AK. Chronic idiopathic urticaria associated with panic disorder: A syndrome responsive to selective serotonin reuptake inhibitor antidepressants? Cutis 56:53-54, 1995.
31. Gorman JM, Liebowitz MR, Fyer AJ, and Stein J. A neuroanatomical hypothesis for panic disorder. Am J Psychiatry 146:148-161, 1989.
32. Jensen K, Tuxen C, Pedersen-Bjergaard U, et al. Pain, wheal, and flare in human forearm skin induced by bradykinin and 5-hydroxytryptamine. Peptides 11:1133-1138, 1990.
33. Rao BS, Das DG, Taraknath VR, and Sarma Y. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India 48:223-226, 2000.
34. Lewis DW, Diamond S, Scott D, and Jones V. Prophylactic treatment of pediatric migraine. Headache 44:230-237, 2004.